DUB be good to me

Xingui Liu; Alessio Ciulli

doi:10.1038/s41589-022-00978-9

DUB be good to me

Xingui Liu, Alessio Ciulli (Lead / Corresponding author)

Biological Chemistry and Drug Discovery

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Induced proximity is reshaping drug discovery. A new study debuts deubiquitinase-targeting chimeras (DUBTACs), small bifunctional molecules that co-opt a deubiquitinase to stabilize a target protein.

Original language	English
Pages (from-to)	358-359
Number of pages	2
Journal	Nature Chemical Biology
Volume	18
Early online date	24 Feb 2022
DOIs	https://doi.org/10.1038/s41589-022-00978-9
Publication status	Published - Apr 2022

Keywords

Chemical tools
Post-translational modifications
Small molecules

ASJC Scopus subject areas

Molecular Biology
Cell Biology

Access to Document

10.1038/s41589-022-00978-9

Cite this

@article{b48b1fb00d524de392d1831483367fb5,

title = "DUB be good to me",

abstract = "Induced proximity is reshaping drug discovery. A new study debuts deubiquitinase-targeting chimeras (DUBTACs), small bifunctional molecules that co-opt a deubiquitinase to stabilize a target protein.",

keywords = "Chemical tools, Post-translational modifications, Small molecules",

author = "Xingui Liu and Alessio Ciulli",

note = "Funding Information: A.C. is a scientific founder, shareholder and advisor of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Nurix Therapeutics and Ono Pharmaceutical.",

year = "2022",

month = apr,

doi = "10.1038/s41589-022-00978-9",

language = "English",

volume = "18",

pages = "358--359",

journal = "Nature Chemical Biology",

issn = "1552-4450",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - DUB be good to me

AU - Liu, Xingui

AU - Ciulli, Alessio

N1 - Funding Information: A.C. is a scientific founder, shareholder and advisor of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Nurix Therapeutics and Ono Pharmaceutical.

PY - 2022/4

Y1 - 2022/4

N2 - Induced proximity is reshaping drug discovery. A new study debuts deubiquitinase-targeting chimeras (DUBTACs), small bifunctional molecules that co-opt a deubiquitinase to stabilize a target protein.

AB - Induced proximity is reshaping drug discovery. A new study debuts deubiquitinase-targeting chimeras (DUBTACs), small bifunctional molecules that co-opt a deubiquitinase to stabilize a target protein.

KW - Chemical tools

KW - Post-translational modifications

KW - Small molecules

UR - http://www.scopus.com/inward/record.url?scp=85125932611&partnerID=8YFLogxK

U2 - 10.1038/s41589-022-00978-9

DO - 10.1038/s41589-022-00978-9

M3 - Article

C2 - 35210617

SN - 1552-4450

VL - 18

SP - 358

EP - 359

JO - Nature Chemical Biology

JF - Nature Chemical Biology

ER -

DUB be good to me

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this